<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36740090</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-0183</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Autoimmunity reviews</Title><ISOAbbreviation>Autoimmun Rev</ISOAbbreviation></Journal><ArticleTitle>COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>103292</StartPage><MedlinePgn>103292</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.autrev.2023.103292</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1568-9972(23)00026-5</ELocationID><Abstract><AbstractText>COVID-19 vaccination has been shown to be safe in patients with systemic lupus erythematosus (SLE), but data on vaccine-associated adverse events (AEs) during the antenatal and lactation period are scarce or lacking. We investigated COVID-19 vaccination-related AEs in pregnant SLE patients from the COVAD study, a global esurvey involving 157 collaborators from 106 countries. A total of 9201 complete responses were extracted. Among 6787 (73.8%) women, we identified 70 (1.1%) who were exposed to at least one COVID-19 vaccine dose during pregnancy, 11 with SLE. Delayed onset (&gt;7&#xa0;days) vaccine-related AEs were triangulated with disease activity, treatment changes due to flare after vaccination, and COVID-19 infections in vaccinated pregnant women. Health-related quality of life and physical function was recorded using PROMIS. Age of patients ranged from 28 to 39&#xa0;years; 5/11 women were of Asian origin. None of these patients reported major vaccine AEs or change in the status of their autoimmune disease. Although minor AEs were common, they did not impair daily functioning, and the symptoms resolved after a median of 3 (IQR: 2.5-5.0) days. All patients reported good to excellent health status. No adverse pregnancy outcomes were reported. Importantly, none of the patients reported thrombotic events post-vaccination, which provides reassurance in a patient population with a high risk for cardiovascular comorbidity and thrombosis, especially in the presence of antiphospholipid antibodies or the antiphospholipid syndrome, a considerable portion of SLE patients. Our findings provide reassurance and can contribute to informed decisions regarding vaccination in patients with SLE and high-risk pregnancies due to their background autoimmune disease. The risk/benefit ratio of COVID-19 vaccination appears favourable, with vaccines both providing passive immunisation to the fetus and active immunisation to the mother with no signals of exacerbation of the mother's autoimmune disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giannopoulou</LastName><ForeName>Nefeli</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; General Hospital of Paphos, University of Nicosia, Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Latika</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India; Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK; Department of Rheumatology, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK; Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreoli</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rheumatology and Clinical Immunology Unit, Azienda Socio-Sanitaria Territoriale Spedali Civili, Brescia, Italy; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lini</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Rheumatology and Clinical Immunology Unit, Azienda Socio-Sanitaria Territoriale Spedali Civili, Brescia, Italy; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVAD Study Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Nikiphorou</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Rheumatic Diseases, King's College London, London, UK; Rheumatology Department, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Rohit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Vikas</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. Electronic address: vikasagr@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parodis</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Department of Rheumatology, Faculty of Medicine and Health, &#xd6;rebro University, &#xd6;rebro, Sweden. Electronic address: ioannis.parodis@ki.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Autoimmun Rev</MedlineTA><NlmUniqueID>101128967</NlmUniqueID><ISSNLinking>1568-9972</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011256" MajorTopicYN="N">Pregnancy Outcome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adverse events</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Pregnancy</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 virus</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest R.A. has a consultancy relationship with and/or has received research funding from Bristol Myers-Squibb, Pfizer, Genentech, Octapharma, CSL Behring, Mallinckrodt, AstraZeneca, Corbus, Kezar, Abbvie, Janssen, Kyverna Alexion, Argenx, Q32, EMD-Serono, Boehringer Ingelheim, Roivant, Merck, Galapagos, Actigraph, Scipher, Horizon Therapeutics, Teva, Beigene, ANI Pharmaceuticals, Biogen, Nuvig, Capella Bioscience, and CabalettaBio. I.P. has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Elli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis, and F. Hoffmann-La Roche AG. The other authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>5</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36740090</ArticleId><ArticleId IdType="pmc">PMC9896878</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2023.103292</ArticleId><ArticleId IdType="pii">S1568-9972(23)00026-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andreoli L., Bertsias G.K., Agmon-Levin N., et al. EULAR recommendations for women&#x2019;s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann. Rheum. Dis. 2017;76(3):476&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446003</ArticleId><ArticleId IdType="pubmed">27457513</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikiphorou E., Joshi M., et al. Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study. Rheumatology (Oxford) 2022 Nov;22:keac661. doi: 10.1093/rheumatology/keac661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac661</ArticleId><ArticleId IdType="pubmed">36413073</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchi F.P., Stefanizzi P., Di Gioia M.C., Brescia N., Lattanzio S., Tafuri S. COVID-19 vaccination hesitancy in pregnant and breastfeeding women and strategies to increase vaccination compliance: a systematic review and meta-analysis. Expert. Rev. Vaccines. 2022;21(10):1443&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pubmed">35818804</ArticleId></ArticleIdList></Reference><Reference><Citation>Grainger R., Kim A.H.J., Conway R., Yazdany J., Robinson P.C. COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nat. Rev. Rheumatol. 2022;18(4):191&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8874732</ArticleId><ArticleId IdType="pubmed">35217850</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq J., Gupta L. Safety and efficacy of COVID-19 vaccines in pregnant women with rheumatic diseases: an immunologic perspective. Rheumatol. Int. 2021;41(8):1545&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8190165</ArticleId><ArticleId IdType="pubmed">34110465</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazal Z.Z., Sen P., Joshi M., et al. COVAD survey 2 long-term outcomes: unmet need and protocol. Rheumatol. Int. 2022;42(12):2151&#x2013;2158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9376047</ArticleId><ArticleId IdType="pubmed">35964271</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou M.G., Andreoli L., Limper M., et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann. Rheum. Dis. 2019;78(10):1296&#x2013;1304.</Citation><ArticleIdList><ArticleId IdType="pubmed">31092409</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>